Series – Page 2 – media

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.
- Source: Xconomy
- 543
- March 5, 2018
cancer immunotherapy Series
Generation Bio Raises $100 Million to Advance Re-Dosable Gene Therapy

Generation Bio said it closed a $100 million series B financing to advance to the clinic its first two therapeutics candidates using its GeneWave platform to develop a new class of genetic medicines with drug-like qualities.
- Source: globalgenes.org
- 497
- March 2, 2018
genetic medicine Market Views Series
XOC PHARMACEUTICALS ANNOUNCES $30 MILLION SERIES A FINANCING LED BY NEA

Company to move forward with novel therapies for migraine and Parkinson’s disease
- Source: xocpharma
- 544
- February 27, 2018
CNS migraine Parkinson’s disease Series
AI Biotech XtalPi Closes Series B Round Funding from Sequoia China, Google, and Tencent

XtalPi Inc., a computation-driven pharmaceutical technology company, announced that it has closed a Series B funding round of 15 million USD led by Sequoia China, with participation from Google and existing investor Tencent. To date, XtalPi has raised over 20 million USD, making it one of the top-funded AI-powered biotechs.
- Source: finance.yahoo
- 521
- February 26, 2018
biotechs Market Views Series
Global Investors Back Rani Therapeutics With $53 Million As Company Moves To Clinical Trials

Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, today announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. This investment brings the total raised to $142 million in funding.
- Source: Prnewswire;
- 517
- February 13, 2018
chronic diseases Clinical Trials Series
Paige.AI Created to Transform Cancer Diagnosis and Treatment by Applying Artificial Intelligence to Pathology

Paige.AI, a new company focused on revolutionizing clinical diagnosis and treatment in oncology through use of artificial intelligence (AI), launches today as it announces two major milestones
- Source: tmcnet
- 562
- February 9, 2018
AI Market Views Series
Tmunity nabs $100M for next-gen T-cell immunotherapies

Tmunity Therapeutics is looking to bring better and safer T-cell therapies for both solid tumors and blood cancers and has scored a $100 million series A to propel it on its journey
- Source: fiercebiotech
- 504
- January 26, 2018
blood cancer Series solid tumor T-cell therapies
Stimwave scoops $50M to step up pain device sales push

Stimwave has raised $50 million to support commercialization of its neuromodulation pain therapies. The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
- Source: fiercebiotech
- 606
- January 19, 2018
Market Views neuromodulation pain therapies Series
TAI Diagnostics Closes $10M Financing and Establishes Collaboration Agreement with United Therapeutics

TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, announced the final closing of a $10 million Series A preferred equity financing. The company has now raised over $21 million since its inception. The proceeds of this financing will support on-going research and development of TAI’s innovative cell-free DNA (cfDNA) transplant monitoring technology, clinical studies, and the upcoming commercial launch of its post-transplant monitoring assays performed by its CLIA and CAP accredited reference laboratory.
- Source: drugdu
- 469
- January 18, 2018
health Series TAI’s innovative cell-free DNA
Alveo Closes $38 Million in Series A Financing to Create Accessible Diagnostics Devices

Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
- Source: Prnewswire
- 399
- January 15, 2018
infectious diseases Market Views Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.